What Is Charcot-Marie-Tooth Neuropathy?

Charcot-Marie-Tooth disease (CMT) is a group of inherited nerve disorders that damage the peripheral nerves, the long cables connecting your brain and spinal cord to your muscles, skin, and sensory organs. It is the most common inherited neurological condition, affecting roughly 1 in 2,500 people worldwide. CMT slowly weakens and wastes the muscles of your feet, lower legs, hands, and forearms, and it often dulls sensation in those same areas. The disease was first described independently in 1886 by two French neurologists, Jean-Martin Charcot and Pierre Marie, and a British physician, Howard Henry Tooth, whose combined names stuck despite none of them fully understanding the genetics behind it.

How CMT Damages Nerves

Your peripheral nerves work a bit like insulated electrical wiring. The nerve fiber itself (the axon) carries the signal, and a fatty sheath called myelin wraps around it, speeding transmission along. CMT can attack either component. In the demyelinating forms, the myelin sheath degrades, slowing signals dramatically. In the axonal forms, the nerve fiber itself breaks down while myelin stays relatively intact. Some subtypes involve both problems at once.

A large clinicopathological study of 205 patients found clear patterns linking specific gene mutations to these two damage types. Patients with the most common mutation, a duplication involving the PMP22 gene, showed mainly demyelinating features with markedly slowed nerve conduction. Patients with mutations in a different gene, MPZ, split into two distinct groups: one that was purely axonal and one that was purely demyelinating, with the specific location of the mutation determining which pattern appeared. Meanwhile, patients with mutations in a gene called Cx32 fell somewhere in between, showing intermediate slowing of nerve signals alongside predominantly axonal damage.¹

That mix-and-match between myelin and axonal damage is part of what makes CMT so variable from person to person, even within the same family. Two siblings carrying the same mutation can differ in how much of each type of damage accumulates, which shapes the severity and pace of their symptoms.

The Genetic Landscape

CMT is not one disease but a family of genetically distinct conditions that produce overlapping symptoms. Over 100 genes have been linked to various CMT subtypes, though a handful account for the vast majority of cases.

The single most common form, CMT1A, is caused by a duplication of a segment of chromosome 17 that results in overproduction of a protein called PMP22, which is essential for myelin. CMT1A accounts for roughly 60 to 70 percent of all CMT cases.² Interestingly, while having an extra copy of PMP22 causes CMT1A, having a deleted copy of the same gene leads to a different condition altogether, called hereditary neuropathy with liability to pressure palsies (HNPP), in which nerves become unusually vulnerable to compression.³

The second most common form overall, CMTX1, results from mutations in GJB1, the gene encoding a gap junction protein called connexin32. Over 400 different mutations in this gene have been identified. These gap junctions help maintain the health of myelinated axons, and when they malfunction, Schwann cells (the cells that produce myelin in peripheral nerves) can no longer support the axons properly.⁴ Because the GJB1 gene sits on the X chromosome, CMTX1 follows X-linked inheritance: men, who carry only one X, tend to be more severely affected, while women, who have a second copy to partially compensate, often have milder symptoms or none at all.

The most common axonal form, CMT2A, is caused by mutations in MFN2, a gene that encodes a protein involved in mitochondrial fusion. When MFN2 malfunctions, mitochondria in nerve cells cannot merge, divide, or travel along axons properly. Research has shown that the damage extends beyond mitochondrial fusion itself, affecting the cleanup of damaged mitochondria and the communication between mitochondria and the cell’s internal transport network.⁵ Lab studies using cells from CMT2A patients found that while some aspects of mitochondrial communication were disrupted, the mitochondria could still generate energy normally, suggesting the disease is more about transport and quality control than about running out of fuel.⁶

Inheritance Patterns and Who Gets It

Most CMT subtypes follow autosomal dominant inheritance, meaning you only need one copy of the faulty gene from one parent to develop the condition. CMT1A fits this pattern. Some forms, grouped under CMT4 and including severe childhood-onset presentations like Dejerine-Sottas disease, follow autosomal recessive inheritance, requiring a faulty copy from both parents.⁷ CMTX1, as noted above, is X-linked. And occasionally, CMT arises from a new spontaneous mutation in someone with no family history at all.

This genetic diversity is one reason CMT is sometimes slow to be diagnosed. A family might carry a dominant mutation for generations with such mild symptoms that nobody seeks medical evaluation until a more severely affected child comes along. Genetic counseling research has highlighted that receiving a CMT diagnosis carries emotional weight well beyond the medical facts, bringing up feelings of grief, guilt over potentially passing on a mutation, and anxiety about progressive disability.⁸

What CMT Looks and Feels Like

The classic symptom package starts in the feet and lower legs. Most people first notice difficulty walking, frequent ankle sprains, or tripping. Muscle wasting in the lower legs can give a characteristic “inverted champagne bottle” appearance. A high-arched foot with curled toes, known as pes cavus, is so strongly associated with CMT that it is often the clinical clue that prompts a referral for nerve testing.⁹ Over time the weakness and sensory loss creep upward and begin affecting the hands, making fine motor tasks like buttoning a shirt or handling coins difficult.

The rate at which this happens varies enormously. Symptom onset can occur anywhere from early childhood to middle age. Most people with CMT1A live full, active lives for decades with manageable limitations. A longitudinal study found that standardized neuropathy scores worsened slowly but measurably, averaging less than one point per year on a clinical scale, though the rate tended to increase with age.¹⁰ A separate study pinpointed age 50 as a tipping point: before that age, the rate of motor decline in CMT1A patients was similar to normal aging, but after 50 the decline accelerated significantly.¹¹

The Symptoms That Get Overlooked

Because CMT is classified as a motor and sensory neuropathy, discussion tends to focus on muscle weakness and numbness. In practice, two other symptoms quietly dominate many patients’ daily lives: fatigue and pain.

A study of 251 CMT patients found that about a third had abnormally high levels of fatigue, compared with only 5 percent of healthy controls. Those with abnormal fatigue also had more severe disease, more hand disability, and greater reliance on walking aids. Perhaps more strikingly, fatigue strongly correlated with anxiety, depression, and general psychological distress, suggesting a feedback loop in which physical limitation and emotional burden amplify each other.¹²

Pain is another underappreciated feature. Overall pain prevalence in one clinical study was about 36 percent, and roughly 15 percent of patients had neuropathic pain specifically, the burning or tingling type caused by nerve damage itself. The pattern of pain varied markedly by subtype: neuropathic pain was significantly more common in CMT1A, while patients with MFN2 mutations (CMT2A) reported no neuropathic pain at all in that cohort.¹³ Musculoskeletal pain from altered gait and joint stress is common too, adding another layer of discomfort that patients do not always connect to their nerve disease.

Getting Diagnosed

Diagnosis typically involves a neurological exam, nerve conduction studies, and genetic testing. Nerve conduction velocity (NCV) is particularly useful for sorting patients into broad categories. In demyelinating CMT, motor nerve conduction slows well below normal. Studies measuring median nerve conduction found average speeds around 20 meters per second in CMT1A, compared with the roughly 50 meters per second seen in healthy nerves.¹⁴ In axonal CMT, conduction speed stays relatively normal, but the size of the electrical signal drops because fewer nerve fibers are functioning.

One important diagnostic pitfall is confusion with an acquired immune-mediated condition called chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). A multicenter study found that CMT patients misdiagnosed as having CIDP were younger at onset, more likely to have motor weakness as their first symptom, and much less likely to respond to immune-based treatments. Only about 20 percent of misdiagnosed CMT patients improved on treatment designed for CIDP, compared with 69 percent of actual CIDP patients.¹⁵ The distinction matters because misdiagnosis can lead to years of expensive and unnecessary immunotherapy. Key clues favoring CMT include a family history of similar symptoms, high-arched feet, hearing loss, and normal or near-normal spinal fluid protein levels.

Managing CMT Day to Day

There is no cure for CMT, so management focuses on maintaining function and preventing complications. The mainstays are orthotic devices, physical therapy, and, when those are not enough, surgery.

Ankle-foot orthoses (AFOs) are the most widely used aids. They stabilize the ankle, reduce tripping, and help compensate for the foot drop that develops as ankle muscles weaken. For hand involvement, a small thumb opposition splint has been shown to improve manual dexterity and performance in daily activities. In a study of 13 patients, hand-function test scores improved significantly with the splint, and patients were satisfied with both its appearance and comfort.¹⁶

When bracing and therapy are no longer enough to manage foot deformities, orthopedic surgery becomes an option. Procedures can include tendon transfers to rebalance pull on the foot, bone cuts to correct arch height, and joint fusions to stabilize the ankle. The goal is functional improvement and pain relief, not cosmetic correction. Surgery is typically considered only after conservative measures like physical therapy and orthoses have been exhausted.¹⁷

Exercise is an area where patients and clinicians have historically been cautious, worrying that working already-damaged muscles too hard might speed decline. The evidence, while still limited, suggests moderate resistance exercise is safe and can help. A systematic review found improvements in strength and functional activities following exercise programs, though the quality of available evidence was moderate at best.¹⁸ A randomized trial in children with CMT tested progressive resistance training over two years and found that ankle strength improved slightly in the exercise group while it declined in the control group, and no serious adverse events occurred.¹⁹ The emerging consensus is that well-supervised moderate exercise helps preserve function without damaging nerves.

Rare but Serious Complications

Most people with CMT retain the ability to walk throughout life, and the disease does not typically shorten lifespan. But in rare cases, particularly with certain mutations, CMT can affect systems beyond the limbs. Respiratory involvement is the most concerning. A study of patients with a specific MPZ mutation found that two had severe restrictive lung disease requiring mechanical ventilation.²⁰ Similarly, a case of autosomal recessive CMT2A linked to MFN2 presented with rapidly progressing weakness of the diaphragm that required a tracheostomy, a dramatic and unusual course for CMT.²¹ These extreme presentations are worth knowing about, not because they are common, but because monitoring lung function can catch problems early in the rare patients at risk.

Experimental Therapies on the Horizon

Because CMT1A is caused by having too much of a single protein, the disease has a surprisingly clean therapeutic target: bring PMP22 levels back to normal. Several strategies are being pursued.

The furthest along in clinical testing is PXT3003, a combination of three repurposed drugs (baclofen, naltrexone, and sorbitol) that aims to reduce PMP22 overexpression. In a randomized, placebo-controlled trial, the high-dose group showed a small but statistically significant improvement on a neuropathy disability scale compared with placebo.²² The results are modest, but given that CMT1A currently has no approved disease-modifying therapy, even a small effect would be meaningful if confirmed in larger follow-up trials.

Gene therapy approaches are earlier-stage but potentially more powerful. Researchers have used a gene-editing tool delivered by an adeno-associated virus (AAV) to target the duplicated PMP22 region in patient-derived stem cells. The treatment reduced PMP22 gene duplication by 20 to 40 percent and normalized protein levels in Schwann cell precursors grown from those cells, correcting both excessive cell death and impaired myelination.²³ A separate group tested delivering an AAV vector directly around the nerves of non-human primates and found that the virus successfully entered up to 90 percent of Schwann cells, reducing PMP22 expression in a dose-dependent way while keeping levels within a healthy range. The injections were well tolerated and safe.²⁴

Gene therapy work is also underway for the axonal form CMT2A. Because MFN2 mutations are often dominant, the defective protein actively interferes with the normal one. Researchers devised a two-pronged approach: use RNA interference to silence both copies of MFN2, then supply a corrected version of the gene that is resistant to the silencing. In motor neurons derived from CMT2A patient stem cells, this combined strategy restored normal mitochondrial distribution along axons and corrected the dysfunctional cleanup of damaged mitochondria. The approach also worked in a mouse model of CMT2A when delivered via the spinal fluid.²⁵

The Search for a Blood-Based Biomarker

One practical challenge with CMT is measuring disease progression. CMT moves slowly, and the clinical scales doctors use rely on physical exams and patient-reported symptoms, which can miss subtle changes over short periods. This makes clinical trials difficult to run, because you need large groups followed for years to detect a drug’s effect.

Researchers have been investigating neurofilament light chain (NfL), a protein released into the blood when nerve fibers are damaged, as a potential biomarker. Studies have consistently found that NfL levels are higher in CMT patients than in healthy people and correlate with disease severity at a single time point.²⁶ The trouble is that NfL does not seem to track changes over time: a three-year follow-up study found no correlation between changes in blood NfL levels and changes in clinical disease scores.²⁷ NfL may reflect cumulative nerve damage rather than ongoing activity, making it useful for confirming a diagnosis or estimating severity but not for monitoring whether a treatment is working. The search for a reliable progression biomarker continues, and it remains one of the key bottlenecks for clinical trial design in CMT.

Living with a Progressive Condition

The psychosocial dimension of CMT often gets less attention than the physical one, but it shapes daily life just as powerfully. Research has identified specific emotional challenges that tend to surface at different stages: younger patients and parents of affected children often grapple with grief over lost independence and anxiety about what the future holds, while adults face practical frustrations around career limitations and the visibility of orthotic devices. Guilt is a recurring theme for parents who have passed on the mutation, and it can complicate family relationships.⁸

Support groups, both online and in person, can help normalize these experiences. Genetic counseling is useful not just for understanding inheritance risk before having children, but also for processing the emotional impact of the diagnosis itself. Many patients find that the uncertainty of progression is harder to cope with than the current level of disability. Having realistic information about how CMT typically evolves, including the fact that most people never need a wheelchair, can relieve some of that anxiety without minimizing the real challenges ahead.